Drug Profile
CDP 492
Latest Information Update: 21 Sep 2007
Price :
$50
*
At a glance
- Originator Celltech Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 24 Jul 2001 Preclinical development for Emesis in United Kingdom (Unknown route)